FDA Revises Leucovorin Approval, Leaving Autism Families in Limbo

The FDA has retracted its earlier endorsement of leucovorin as a treatment for autism, now approving it only for a rare genetic disorder affecting fewer than 50 individuals globally. This decision has left many parents feeling betrayed, as they had pinned their hopes on the drug for their children. Experts agree that the evidence supporting leucovorin for autism is insufficient, urging families to consult with their healthcare providers. Despite the FDA's stance, interest in the drug and related testing remains high, with some families still seeking prescriptions. Parents are cautioned about potential exploitation by unregulated providers in light of the drug's uncertain future.

Key Details: • FDA's new approval limits leucovorin use to a rare genetic condition. • Families are encouraged to consult their doctors regarding treatment options. • Leucovorin prescriptions surged following initial endorsements last fall. • Testing for the folate receptor autoantibody costs nearly $300 and is not covered by insurance. • Parents should be wary of unregulated providers taking advantage of their situation.